Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Method of treating fungal infection
US9993534B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9993534-B2 |
| Application number | US-201414203898-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2014 |
| Priority date | Mar 12, 2013 |
| Publication date | Jun 12, 2018 |
| Grant date | Jun 12, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A vaccine comprising Calnexin fragment and a method of using the vaccine to immunize a patient against fungi are disclosed. The Calnexin fragment may be either a full-length native version or a functionally equivalent version of full-length Calnexin.
First claim
Opening claim text (preview).
We claim: 1. A vaccine to immunize a patient against fungi, wherein the vaccine comprises a therapeutically effective amount of Calnexin peptide or Calnexin fragment, wherein the vaccine further comprises a therapeutically effective amount of an adjuvant, wherein the Calnexin peptide or Calnexin fragment consists of SEQ ID NO:1. 2. The vaccine of claim 1 , additionally comprising at least one of a stabilizer or a buffer. 3. A method of protecting a patient from fungal infection comprising of the steps of: a. obtaining the vaccine of claim 1 , wherein the vaccine comprises a Calnexin fragment and b. providing a therapeutically effective amount of the vaccine to a subject, wherein the subject is protected from fungal infection. 4. The method of claim 3 , wherein the fungi are either dimorphic fungi or non-dimorphic fungi. 5. The method of claim 4 , wherein the dimorphic fungi are selected from a group consisting of Histoplasma, Coccidiodes, Paracoccidioides, Penicillium, Blastomyces , and Sporothrix. 6. The method of claim 4 , wherein the non-dimorphic fungi are selected from a group consisting of Aspergillus, Pneumocystis, Magnaportha, Exophiala, Neuroaspora, Cryptococcus, Schizophyllum , and Candida. 7. The method of claim 3 , wherein the Calnexin fragment of step (a) is expressed and isolated from E. Coli.
Assignees
Inventors
Classifications
Emulsions, e.g. Freund's adjuvant, MF59 · CPC title
against material from fungi, algea or lichens · CPC title
characterised by the dose, timing or administration schedule · CPC title
from fungi · CPC title
- A61K39/0002Primary
Fungal antigens, e.g. Trichophyton, Aspergillus, Candida · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9993534B2 cover?
- A vaccine comprising Calnexin fragment and a method of using the vaccine to immunize a patient against fungi are disclosed. The Calnexin fragment may be either a full-length native version or a functionally equivalent version of full-length Calnexin.
- Who is the assignee on this patent?
- Wisconsin Alumni Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0002. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).